Engineers Gate Manager’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Engineers Gate Manager’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,945	Closed	-$968K	–	2377
2022 Q1	$968K	Buy	27,945 +3,668	+15%	+$110K	0.04%	692
2021 Q4	$711K	Sell	24,277 -3,091	-11%	-$95.7K	0.03%	817
2021 Q3	$697K	Buy	+27,368	New	+$804K	0.04%	689
2020 Q4	–	Sell	-15,569	Closed	-$858K	–	2085
2020 Q3	$858K	Buy	+15,569	New	+$989K	0.04%	707
2020 Q1	–	Sell	-5,030	Closed	-$400K	–	2047
2019 Q4	$400K	Buy	+5,030	New	+$298K	0.02%	1107

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Engineers Gate Manager's GBT Position: Q2 2022 in Review

Engineers Gate Manager sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 27,945 shares — an estimated $968K sold.

Engineers Gate Manager first reported a position in GBT in Q4 2019 and held it in 5 quarters. The position peaked at $968K in Q1 2022. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

Engineers Gate Manager reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Engineers Gate Manager sold 27,945 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $968K.
Engineers Gate Manager first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 5 quarters.
Engineers Gate Manager's Global Blood Therapeutics, Inc. position peaked at $968K in Q1 2022.
195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Engineers Gate Manager's 13F filing for Q2 2022, filed 15 Aug 2022.